CARDERO RESOURCE
🇩🇪XFRA.CR5GermanyNot reported
Price€8.02-0.28 (-3.37%)
Latest anomalies
Neutral 1 detected in the last 120 days
- High: 0
- Medium: 0
- Low: 1
Overnight gap: a gap down from the prior close
Free with a Finzer account.
Profile
- Germany
Identity
- Exchange
- Frankfurt Stock Exchange . XFRA
- Type
- Stock
- ISIN
- Not reported
- CUSIP
- Not reported
Company
- Employees
- 49
- Headquarters
- Zug, Germany
- Website
- https://oculis.com
Market
- Shares outstanding
- 55.5M
- Market cap
- €463.61M
Highlights
- Market cap
- €463.61M
- EPS LTM
- -CHF 1.86calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- Not reported
- Div yield
- 0%
Fundamentals (LTM)
- Revenue
- CHF 00%unchanged year on year
- Net income
- -CHF 107.43M-60.72%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CHF 57.68M-10.98%down year on year
Latest news
News is not sourced for this exchange.
Business summary
CARDERO RESOURCE is listed on Frankfurt Stock Exchange (Germany) under the ticker CR5. Its market capitalisation is €463.61M, from 55.5M shares outstanding, as of . Across the 250 trading sessions to the shares traded between €7.86 and €29.30, and the last close of €8.02 sits 1% of the way up that range. The company is headquartered in Zug, Germany, and employs about 49 people. This is the Frankfurt Stock Exchange listing of CARDERO RESOURCE; its primary listing is CR5 on Stuttgart Stock Exchange.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.